Share-based Payment Arrangement, Expense of UNITED THERAPEUTICS Corp from 31 Dec 2015 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
UNITED THERAPEUTICS Corp quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2015 to 30 Sep 2025.
  • UNITED THERAPEUTICS Corp Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $39,100,000, a 6.2% decline year-over-year.
  • UNITED THERAPEUTICS Corp Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $135,700,000, a 1.6% increase year-over-year.
  • UNITED THERAPEUTICS Corp annual Share-based Payment Arrangement, Expense for 2024 was $144,000,000, a 268% increase from 2023.
  • UNITED THERAPEUTICS Corp annual Share-based Payment Arrangement, Expense for 2023 was $39,100,000, a 63% decline from 2022.
  • UNITED THERAPEUTICS Corp annual Share-based Payment Arrangement, Expense for 2022 was $106,800,000, a 23% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

UNITED THERAPEUTICS Corp Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $135,700,000 $39,100,000 -$2,600,000 -6.2% 01 Jul 2025 30 Sep 2025 10-Q 29 Oct 2025 2025 Q3
Q2 2025 $138,300,000 $37,800,000 -$11,900,000 -24% 01 Apr 2025 30 Jun 2025 10-Q 30 Jul 2025 2025 Q2
Q1 2025 $150,200,000 $31,800,000 +$6,200,000 +24% 01 Jan 2025 31 Mar 2025 10-Q 30 Apr 2025 2025 Q1
Q4 2024 $144,000,000 $27,000,000 +$10,400,000 +63% 01 Oct 2024 31 Dec 2024 10-K 26 Feb 2025 2024 FY
Q3 2024 $133,600,000 $41,700,000 +$20,600,000 +98% 01 Jul 2024 30 Sep 2024 10-Q 29 Oct 2025 2025 Q3
Q2 2024 $113,000,000 $49,700,000 +$35,900,000 +260% 01 Apr 2024 30 Jun 2024 10-Q 30 Jul 2025 2025 Q2
Q1 2024 $77,100,000 $25,600,000 +$38,000,000 01 Jan 2024 31 Mar 2024 10-Q 30 Apr 2025 2025 Q1
Q4 2023 $39,100,000 $16,600,000 -$48,200,000 -74% 01 Oct 2023 31 Dec 2023 10-K 26 Feb 2025 2024 FY
Q3 2023 $87,300,000 $21,100,000 +$23,500,000 01 Jul 2023 30 Sep 2023 10-Q 30 Oct 2024 2024 Q3
Q2 2023 $63,800,000 $13,800,000 -$51,700,000 -79% 01 Apr 2023 30 Jun 2023 10-Q 31 Jul 2024 2024 Q2
Q1 2023 $115,500,000 $12,400,000 +$8,700,000 +41% 01 Jan 2023 31 Mar 2023 10-Q 01 May 2024 2024 Q1
Q4 2022 $106,800,000 $64,800,000 +$20,100,000 +45% 01 Oct 2022 31 Dec 2022 10-K 26 Feb 2025 2024 FY
Q3 2022 $86,700,000 $2,400,000 -$27,000,000 -110% 01 Jul 2022 30 Sep 2022 10-Q 01 Nov 2023 2023 Q3
Q2 2022 $113,700,000 $65,500,000 +$36,400,000 +125% 01 Apr 2022 30 Jun 2022 10-Q 02 Aug 2023 2023 Q2
Q1 2022 $77,300,000 $21,100,000 -$61,200,000 -153% 01 Jan 2022 31 Mar 2022 10-Q 03 May 2023 2023 Q1
Q4 2021 $138,500,000 $44,700,000 -$49,000,000 -52% 01 Oct 2021 31 Dec 2021 10-K 21 Feb 2024 2023 FY
Q3 2021 $187,500,000 $24,600,000 +$37,100,000 01 Jul 2021 30 Sep 2021 10-Q 02 Nov 2022 2022 Q3
Q2 2021 $150,400,000 $29,100,000 -$22,700,000 -44% 01 Apr 2021 30 Jun 2021 10-Q 03 Aug 2022 2022 Q2
Q1 2021 $173,100,000 $40,100,000 +$9,300,000 +30% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022 2022 Q1
Q4 2020 $163,800,000 $93,700,000 +$64,200,000 +218% 01 Oct 2020 31 Dec 2020 10-K 22 Feb 2023 2022 FY
Q3 2020 $99,600,000 $12,500,000 -$36,400,000 -152% 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021 2021 Q3
Q2 2020 $136,000,000 $51,800,000 +$89,000,000 01 Apr 2020 30 Jun 2020 10-Q 04 Aug 2021 2021 Q2
Q1 2020 $47,000,000 $30,800,000 +$1,600,000 +5.5% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021 2021 Q1
Q4 2019 $45,400,000 $29,500,000 +$26,700,000 +954% 01 Oct 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
Q3 2019 $18,700,000 $23,900,000 -$27,500,000 -54% 01 Jul 2019 30 Sep 2019 10-Q 28 Oct 2020 2020 Q3
Q2 2019 $46,200,000 $37,200,000 -$57,700,000 -281% 01 Apr 2019 30 Jun 2019 10-Q 29 Jul 2020 2020 Q2
Q1 2019 $103,900,000 $29,200,000 +$130,300,000 01 Jan 2019 31 Mar 2019 10-Q 29 Apr 2020 2020 Q1
Q4 2018 $26,400,000 $2,800,000 -$115,700,000 -98% 01 Oct 2018 31 Dec 2018 10-K 24 Feb 2021 2020 FY
Q3 2018 $89,300,000 $51,400,000 +$75,400,000 01 Jul 2018 30 Sep 2018 10-Q 30 Oct 2019 2019 Q3
Q2 2018 $13,900,000 $20,500,000 +$22,400,000 01 Apr 2018 30 Jun 2018 10-Q 31 Jul 2019 2019 Q2
Q1 2018 $8,500,000 $101,100,000 -$82,000,000 -429% 01 Jan 2018 31 Mar 2018 10-Q 01 May 2019 2019 Q1
Q4 2017 $73,500,000 $118,500,000 01 Oct 2017 31 Dec 2017 10-K 26 Feb 2020 2019 FY
Q3 2017 $24,000,000 01 Jul 2017 30 Sep 2017 10-Q 31 Oct 2018 2018 Q3
Q2 2017 $1,900,000 01 Apr 2017 30 Jun 2017 10-Q 01 Aug 2018 2018 Q2
Q1 2017 $19,100,000 01 Jan 2017 31 Mar 2017 10-Q 02 May 2018 2018 Q1

UNITED THERAPEUTICS Corp Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $144,000,000 +$104,900,000 +268% 01 Jan 2024 31 Dec 2024 10-K 26 Feb 2025 2024 FY
2023 $39,100,000 -$67,700,000 -63% 01 Jan 2023 31 Dec 2023 10-K 26 Feb 2025 2024 FY
2022 $106,800,000 -$31,700,000 -23% 01 Jan 2022 31 Dec 2022 10-K 26 Feb 2025 2024 FY
2021 $138,500,000 -$25,300,000 -15% 01 Jan 2021 31 Dec 2021 10-K 21 Feb 2024 2023 FY
2020 $163,800,000 +$118,400,000 +261% 01 Jan 2020 31 Dec 2020 10-K 22 Feb 2023 2022 FY
2019 $45,400,000 +$71,800,000 01 Jan 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
2018 $26,400,000 -$99,900,000 -136% 01 Jan 2018 31 Dec 2018 10-K 24 Feb 2021 2020 FY
2017 $73,500,000 +$61,400,000 +507% 01 Jan 2017 31 Dec 2017 10-K 26 Feb 2020 2019 FY
2016 $12,100,000 -$268,200,000 -96% 01 Jan 2016 31 Dec 2016 10-K 27 Feb 2019 2018 FY
2015 $280,300,000 01 Jan 2015 31 Dec 2015 10-K 21 Feb 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.